萊美藥業(300006.SZ):擬轉讓成都美康35%股權及四川美康2.25%股權
格隆匯 2 月 8日丨萊美藥業(300006.SZ)公佈,四川美康醫藥軟件研究開發有限公司(“四川美康”)和成都美康醫藥信息系統有限公司(“成都美康”)系公司參與投資設立的常州萊美青楓醫藥產業投資中心(有限合夥)(“萊美青楓”)對外投資企業,四川美康和成都美康系公司聯營企業。四川美康主營業務為臨牀醫藥信息數據庫,包括具有處方審查功能的合理用藥監測系統(PASS)、集成國內外權威臨牀信息的合理用藥信息支持系統(MCDEX)和上市藥品標準化基礎數據庫信息系統(CDD)等醫藥信息化產品。成都美康持有四川美康95%的股權,不從事具體業務,由四川美康作為主要業務經營主體。2018年11月和2019年1月,公司參與投資設立的萊美青楓通過股權受讓方式取得成都美康35%股權和四川美康2.25%股權。
為進一步聚焦優勢細分領域,公司於2021年2月5日召開的第五屆董事會第十二次會議和第五屆監事會第九次會議分別審議通過了《關於轉讓聯營企業股權的議案》,同意公司將通過萊美青楓持有的成都美康35%股權、四川美康2.25%股權分別以人民幣1.995億元、1350萬元轉讓給自然人賴琪。此次股權轉讓交易完成後,公司將不再間接持有聯營企業四川美康和成都美康股權。
四川美康主營業務為醫藥軟件技術開發,成都美康系四川美康控股股東,四川美康和成都美康主營業務不符合公司未來發展戰略規劃。此次公司通過萊美青楓轉讓間接持有的四川美康和成都美康股權將有利於更好地配置公司資源、優化資產結構、提高資產運營效率,有利於公司進一步聚焦主業促進核心業務的整體穩定發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.